Unlearn, a leader in AI-powered clinical trial solutions, has named Kwame Marfo as its first Vice President of Product. With over 15 years of experience in life sciences, health technology, and product innovation, Marfo will drive the development of Unlearn’s digital twin technology, which aims to accelerate clinical research and improve efficiency for pharmaceutical partners. His appointment underscores Unlearn’s commitment to transforming clinical trials through innovative AI solutions.
Kwame Marfo appointed as Unlearn’s first Vice President of Product.
Brings 15+ years of expertise in life sciences and health technology.
Will lead product strategy for AI-driven digital twin technology.
Previously held leadership roles at Komodo Health and Genentech.
Focuses on aligning solutions with pharmaceutical and regulatory needs.
Aims to enhance trial efficiency and patient-centric outcomes.
Kwame Marfo joins Unlearn with extensive experience in clinical operations and product strategy, positioning him to advance the company’s mission. “Kwame brings the rare combination of deep domain expertise and a sharp product mindset that will be invaluable as we continue to scale,” said Steve Herne, CEO of Unlearn. Marfo will oversee product strategy, ensuring Unlearn’s digital twin technology aligns with the needs of pharmaceutical partners and global regulatory bodies to streamline clinical trials.
Marfo’s prior role as Senior Director of Product Strategy and Incubation at Komodo Health involved leading cross-functional teams to develop products for clinical development and medical affairs. At Genentech, he spent over a decade in leadership roles, including co-founding the Insights & Analytics function for Global Clinical Operations, which improved trial representation, patient experience, and timelines. “Unlearn is tackling one of the most longstanding challenges in healthcare by modernizing clinical trials and helping bring effective treatments to patients faster,” said Marfo. “I’m excited to join a team that’s not only leading in AI innovation, but also rethinking legacy systems with a deep commitment to scientific rigor and real-world patient impact.”
Unlearn’s digital twin technology uses AI to predict patient outcomes, enabling smaller, more efficient clinical trials with reduced control group sizes. Marfo’s leadership will focus on refining these solutions to meet industry demands, optimizing trial power, and accelerating drug development. His expertise will ensure Unlearn’s offerings remain at the forefront of clinical trial innovation, delivering measurable value to sponsors and patients.
Unlearn’s AI solutions are backed by regulatory endorsements from the EMA and FDA, reflecting its science-first approach. Marfo’s strategic vision will strengthen Unlearn’s ability to deliver compliant, patient-centric solutions that enhance trial outcomes. His leadership will support expanded partnerships with leading pharmaceutical and biotech firms, driving innovation in clinical research.
With Kwame Marfo as Vice President of Product, Unlearn is well-positioned to advance its AI-driven clinical trial solutions. His expertise and vision will accelerate the development of efficient, patient-focused trials, reinforcing Unlearn’s role as a leader in transforming clinical research for faster delivery of life-saving treatments.
Unlearn partners with pharma and biotech companies to design and optimize clinical trials using AI-powered digital twins. By forecasting patients’ clinical outcomes, Unlearn helps sponsors refine trial design, shorten timelines, and increase the chance of detecting treatment effects in less time. With a science-first approach and deep regulatory engagement—including EMA qualification and FDA endorsement—Unlearn is transforming clinical development to be faster, smarter, and more reliable.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.